Pancreatic cancer chemoprevention by phytochemicals

Cancer Letters

Volumn 334, Issue 1, 2013, Pages 86-94

  Boreddy, Srinivas Reddy ^a   Srivastava, Sanjay K ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Benzyl isothiocyanate; Capsaicin; Curcumin; Green tea; Resveratrol

Indexed keywords

BENZYL ISOTHIOCYANATE; CAPSAICIN; CURCUMIN; GREEN TEA EXTRACT; RESVERATROL; ANTINEOPLASTIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; PLANT MEDICINAL PRODUCT; STILBENE DERIVATIVE; TEA;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; FRUIT; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYTOCHEMISTRY; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL RATE; TEA; VEGETABLE; CHEMISTRY; PANCREATIC NEOPLASMS;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAPSAICIN; CURCUMIN; HUMANS; ISOTHIOCYANATES; PANCREATIC NEOPLASMS; PHYTOCHEMICALS; STILBENES; TEA;

EID: 84891917085     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.020     Document Type: Review

References (124)

1. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
2. Zhang Y., Li M., Wang H., Fisher W.E., Lin P.H., Yao Q., Chen C. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World Journal of Surgery 2009, 33:698-709.
3. Szafranska A.E., Davison T.S., John J., Cannon T., Sipos B., Maghnouj A., Labourier E., Hahn S.A. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007, 26:4442-4452.
4. Costello E., Neoptolemos J.P. Pancreatic cancer in 2010: new insights for early intervention and detection. Nature Reviews Gastroenterology and Hepatology 2010, 8(2011):71-73.
5. Shore S., Raraty M.G., Ghaneh P., Neoptolemos J.P. Review article: chemotherapy for pancreatic cancer. Alimentary Pharmacology and Therapeutics 2003, 18:1049-1069.
6. Block G., Patterson B., Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutrition and Cancer 1992, 18:1-29.
7. Aggarwal B.B., Sundaram C., Malani N., Ichikawa H. Curcumin: the Indian solid gold. Advances in Experimental Medicine and Biology 2007, 595:1-75.
8. Strimpakos A.S., Sharma R.A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxidants and Redox Signaling 2008, 10:511-545.
9. Jutooru I., Chadalapaka G., Lei P., Safe S. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. The Journal of Biological Chemistry 2010, 285:25332-25344.
10. Li L., Aggarwal B.B., Shishodia S., Abbruzzese J., Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004, 101:2351-2362.
11. Glienke W., Maute L., Wicht J., Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Investigation 2010, 28:166-171.
12. Wang Z., Zhang Y., Banerjee S., Li Y., Sarkar F.H. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006, 106:2503-2513.
13. Padhye S., Banerjee S., Chavan D., Pandye S., Swamy K.V., Ali S., Li J., Dou Q.P., Sarkar F.H. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharmaceutical Research 2009, 26:2438-2445.
14. Sahu R.P., Batra S., Srivastava S.K. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. British Journal of Cancer 2009, 100:1425-1433.
15. Glienke W., Maute L., Wicht J., Bergmann L. Wilms' tumour gene 1 (WT1) as a target in curcumin treatment of pancreatic cancer cells. European Journal of Cancer 2009, 45:874-880.
16. Hidaka H., Ishiko T., Furuhashi T., Kamohara H., Suzuki S., Miyazaki M., Ikeda O., Mita S., Setoguchi T., Ogawa M. Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface.impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer 2002, 95:1206-1214.
17. Kunnumakkara A.B., Guha S., Krishnan S., Diagaradjane P., Gelovani J., Aggarwal B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Research 2007, 67:3853-3861.
18. Lin L., Hutzen B., Zuo M., Ball S., Deangelis S., Foust E., Pandit B., Ihnat M.A., Shenoy S.S., Kulp S., Li P.K., Li C., Fuchs J., Lin J. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Research 2010, 70:2445-2454.
19. Hutzen B., Friedman L., Sobo M., Lin L., Cen L., De Angelis S., Yamakoshi H., Shibata H., Iwabuchi Y., Lin J. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. International Journal of Oncology 2009, 35:867-872.
20. Gu L., Chiang K.Y., Zhu N., Findley H.W., Zhou M. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Experimental Hematology 2007, 35:957-966.
21. Bora-Tatar G., Dayangac-Erden D., Demir A.S., Dalkara S., Yelekci K., Erdem-Yurter H. Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies. Bioorganic Medicinal Chemistry 2009, 17:5219-5228.
22. Liu H.L., Chen Y., Cui G.H., Zhou J.F. Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacologica Sinica 2005, 26:603-609.
23. Meja K.K., Rajendrasozhan S., Adenuga D., Biswas S.K., Sundar I.K., Spooner G., Marwick J.A., Chakravarty P., Fletcher D., Whittaker P., Megson I.L., Kirkham P.A., Rahman I. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. American Journal of Respiratory Cell and Molecular Biology 2008, 39:312-323.
24. Balasubramanyam K., Varier R.A., Altaf M., Swaminathan V., Siddappa N.B., Ranga U., Kundu T.K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. The Journal of Biological Chemistry 2004, 279:51163-51171.
25. Liu Z., Xie Z., Jones W., Pavlovicz R.E., Liu S., Yu J., Li P.K., Lin J., Fuchs J.R., Marcucci G., Li C., Chan K.K. Curcumin is a potent DNA hypomethylation agent. Bioorganic and Medicinal Chemistry Letters 2009, 19:706-709.
26. Medina-Franco J.L., Lopez-Vallejo F., Kuck D., Lyko F. Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach. Molecular Diversity 2011, 15:293-304.
27. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nature Reviews Cancer 2006, 6:857-866.
28. Rachagani S., Kumar S., Batra S.K. MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Letters 2010, 292:8-16.
29. Ali S., Ahmad A., Aboukameel A., Bao B., Padhye S., Philip P.A., Sarkar F.H. Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Cancer Letters 2012, 319:173-181.
30. Bao B., Ali S., Banerjee S., Wang Z., Logna F., Azmi A.S., Kong D., Ahmad A., Li Y., Padhye S., Sarkar F.H. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Research 2012, 72:335-345.
31. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J.M., Wang Z., Philip P.A., Sarkar F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Research 2010, 70:3606-3617.
32. Sun M., Estrov Z., Ji Y., Coombes K.R., Harris D.H., Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Molecular Cancer Therapeutics 2008, 7:464-473.
33. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics 2007, 4:807-818.
34. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica 1998, 64:353-356.
35. Kanai M., Yoshimura K., Asada M., Imaizumi A., Suzuki C., Matsumoto S., Nishimura T., Mori Y., Masui T., Kawaguchi Y., Yanagihara K., Yazumi S., Chiba T., Guha S., Aggarwal B.B. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemotherapy and Pharmacology 2011, 68:157-164.
36. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., Ng C.S., Badmaev V., Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:4491-4499.
37. Zhang Y., Talalay P., Cho C.G., Posner G.H. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:2399-2403.
38. Stoner G.D., Morse M.A. Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Cancer Letters 1997, 114:113-119.
39. Shapiro T.A., Fahey J.W., Wade K.L., Stephenson K.K., Talalay P. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. Cancer Epidemiology, Biomarkers and Prevention 2001, 10:501-508.
40. Boreddy S.R., Sahu R.P., Srivastava S.K. Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-alpha/VEGF/Rho-GTPases: pivotal role of STAT-3. PloS One 2011, 6:e25799.
41. Boreddy S.R., Pramanik K.C., Srivastava S.K. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clinical Cancer Research 2011, 17:1784-1795.
42. Batra S., Sahu R.P., Kandala P.K., Srivastava S.K. Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Molecular Cancer Therapeutics 2010, 9:1596-1608.
43. Sahu R.P., Zhang R., Batra S., Shi Y., Srivastava S.K. Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells. Carcinogenesis 2009, 30:1744-1753.
44. Sahu R.P., Epperly M.W., Srivastava S.K. Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation therapy. Frontiers in Bioscience (Elite Ed) 2009, 1:568-576.
45. Sahu R.P., Srivastava S.K. The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. Journal of the National Cancer Institute 2009, 101:176-193.
46. Zhang R., Loganathan S., Humphreys I., Srivastava S.K. Benzyl isothiocyanate-induced DNA damage causes G2/M cell cycle arrest and apoptosis in human pancreatic cancer cells. The Journal of Nutrition 2006, 136:2728-2734.
47. Srivastava S.K., Singh S.V. Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis 2004, 25:1701-1709.
48. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., Peng Z., Huang S., Xiong H.Q., Abbruzzese J.L., Xie K. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003, 22:319-329.
49. Darnell J.E. Validating Stat3 in cancer therapy. Nature medicine 2005, 11:595-596.
50. Semenza G.L. HIF-1 and mechanisms of hypoxia sensing. Current Opinion in Cell Biology 2001, 13:167-171.
51. Xu Q., Briggs J., Park S., Niu G., Kortylewski M., Zhang S., Gritsko T., Turkson J., Kay H., Semenza G.L., Cheng J.Q., Jove R., Yu H. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 24:5552-5560.
52. Jung J.E., Lee H.G., Cho I.H., Chung D.H., Yoon S.H., Yang Y.M., Lee J.W., Choi S., Park J.W., Ye S.K., Chung M.H. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB Journal 2005, 19:1296-1298.
53. A. Finkielsztein, G.M. Kelly, Altering PI3K-Akt signalling in zebrafish embryos affects PTEN phosphorylation and gastrulation. Biology of the Cell. 101 (2009) 661-678, 664 p. (following 678).
54. Schlieman M.G., Fahy B.N., Ramsamooj R., Beckett L., Bold R.J. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. British Journal of Cancer 2003, 89:2110-2115.
55. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
56. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
57. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology 1998, 16:225-260.
58. Sun Z., Andersson R. NF-kappaB activation and inhibition: a review. Shock 2002, 18:99-106.
59. Bode A.M., Dong Z. The two faces of capsaicin. Cancer Research 2011, 71:2809-2814.
60. Hoch-Ligeti C. Production of liver tumours by dietary means; effect of feeding chilies [Capsicum frutescens and annuum (Linn.)] to rats. Acta - Unio Internationalis Contra Cancrum 1951, 7:606-611.
61. Toth B., Gannett P. Carcinogenicity of lifelong administration of capsaicin of hot pepper in mice. In Vivo 1992, 6:59-63.
62. Zhang R., Humphreys I., Sahu R.P., Shi Y., Srivastava S.K. In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Apoptosis 2008, 13:1465-1478.
63. Pramanik K.C., Boreddy S.R., Srivastava S.K. Role of mitochondrial electron transport chain complexes in capsaicin mediated oxidative stress leading to apoptosis in pancreatic cancer cells. PloS One 2011, 6:e20151.
64. Pramanik K.C., Srivastava S.K. Apoptosis signal-regulating kinase 1-thioredoxin complex dissociation by capsaicin causes pancreatic tumor growth suppression by inducing apoptosis. Antioxidants and Redox Signaling 2012, 17:1417-1432.
65. Bai H., Li H., Zhang W., Matkowskyj K.A., Liao J., Srivastava S.K., Yang G.Y. Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice. Carcinogenesis 2011, 32:1689-1696.
66. Serra I., Yamamoto M., Calvo A., Cavada G., Baez S., Endoh K., Watanabe H., Tajima K. Association of chili pepper consumption, low socioeconomic status and longstanding gallstones with gallbladder cancer in a Chilean population. International Journal of Cancer 2002, 102:407-411.
67. Lopez-Carrillo L., Hernandez Avila M., Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-control study. American Journal of Epidemiology 1994, 139:263-271.
68. Dasgupta P., Chandiramani V., Parkinson M.C., Beckett A., Fowler C.J. Treating the human bladder with capsaicin: is it safe?. European Urology 1998, 33:28-31.
69. Nishitoh H., Saitoh M., Mochida Y., Takeda K., Nakano H., Rothe M., Miyazono K., Ichijo H. ASK1 is essential for JNK/SAPK activation by TRAF2. Molecular Cell 1998, 2:389-395.
70. Cabrera C., Artacho R., Gimenez R. Beneficial effects of green tea-a review. Journal of the American College of Nutrition 2006, 25:79-99.
71. McKay D.L., Blumberg J.B. The role of tea in human health: an update. Journal of the American College of Nutrition 2002, 21:1-13.
72. Okushio K., Matsumoto N., Kohri T., Suzuki M., Nanjo F., Hara Y. Absorption of tea catechins into rat portal vein. Biological and Pharmaceutical Bulletin 1996, 19:326-329.
73. Lee M.J., Maliakal P., Chen L., Meng X., Bondoc F.Y., Prabhu S., Lambert G., Mohr S., Yang C.S. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiology, Biomarkers and Prevention 2002, 11:1025-1032.
74. Yang C.S., Wang X. Green tea and cancer prevention. Nutrition and Cancer 2010, 62:931-937.
75. Zhang L., Pang E., Loo R.R., Rao J., Go V.L., Loo J.A., Lu Q.Y. Concomitant inhibition of HSP90, its mitochondrial localized homologue TRAP1 and HSP27 by green tea in pancreatic cancer HPAF-II cells. Proteomics 2011, 11:4638-4647.
76. Li Y., Zhang T., Jiang Y., Lee H.F., Schwartz S.J., Sun D. (-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2. Molecular Pharmaceutics 2009, 6:1152-1159.
77. Qanungo S., Das M., Haldar S., Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 2005, 26:958-967.
78. Shankar S., Suthakar G., Srivastava R.K. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Frontiers in Bioscience 2007, 12:5039-5051.
79. Tang S.N., Fu J., Nall D., Rodova M., Shankar S., Srivastava R.K. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. International Journal of Cancer 2012, 131:30-40.
80. Kostin S.F., McDonald D.E., McFadden D.W. Inhibitory effects of (-)-epigallocatechin-3-gallate and pterostilbene on pancreatic cancer growth in vitro. Journal of Surgical Research 2012, 177:255-262.
81. Hardtner C., Multhoff G., Falk W., Radons J. (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. European Journal of Pharmacology 2012, 684:36-43.
82. Basu A., Haldar S. Combinatorial effect of epigallocatechin-3-gallate and TRAIL on pancreatic cancer cell death. International Journal of Oncology 2009, 34:281-286.
83. Tan M., Norwood A., May M., Tucci M., Benghuzzi H. Effects of (-)epigallocatechin gallate and thymoquinone on proliferation of a PANC-1 cell line in culture. Biomedical Sciences Instrumentation 2006, 42:363-371.
84. Tang S.N., Fu J., Shankar S., Srivastava R.K. EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PloS One 2012, 7:e31067.
85. Shankar S., Ganapathy S., Hingorani S.R., Srivastava R.K. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Frontiers in Bioscience 2008, 13:440-452.
86. Vu H.A., Beppu Y., Chi H.T., Sasaki K., Yamamoto H., Xinh P.T., Tanii T., Hara Y., Watanabe T., Sato Y., Ohdomari I. Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. Journal of Biomedical Biotechnology 2010, 2010:290516.
87. Zhu B.H., Chen H.Y., Zhan W.H., Wang C.Y., Cai S.R., Wang Z., Zhang C.H., He Y.L. (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. World Journal of Gastroenterology 2011, 17:2315-2325.
88. Takabayashi F., Tahara S., Kaneko T., Harada N. Effect of green tea catechins on oxidative DNA damage of hamster pancreas and liver induced by N-Nitrosobis(2-oxopropyl)amine and/or oxidized soybean oil. Biofactors 2004, 21:335-337.
89. Majima T., Tsutsumi M., Nishino H., Tsunoda T., Konishi Y. Inhibitory effects of beta-carotene, palm carotene, and green tea polyphenols on pancreatic carcinogenesis initiated by N-nitorsobis(2-oxopropyl)amine in Syrian golden hamsters. Pancreas 1998, 16:13-18.
90. Hiura A., Tsutsumi M., Satake K. Inhibitory effect of green tea extract on the process of pancreatic carcinogenesis induced by N-nitrosobis-(2-oxypropyl)amine (BOP) and on tumor promotion after transplantation of N-nitrosobis-(2-hydroxypropyl)amine (BHP)-induced pancreatic cancer in Syrian hamsters. Pancreas 1997, 15:272-277.
91. Thakur V.S., Gupta K., Gupta S. Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. International Journal of Oncology 2012, 41:353-361.
92. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., Welsh W., Yang C.S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Research 2003, 63:7563-7570.
93. Pandey M., Shukla S., Gupta S. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. International Journal of Cancer 2010, 126:2520-2533.
94. Tsang W.P., Kwok T.T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. Journal of Nutritional Biochemistry 2010, 21:140-146.
95. Penumathsa S.V., Maulik N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Canadian Journal of Physiology and Pharmacology 2009, 87:275-286.
96. Baliga M.S., Meleth S., Katiyar S.K. Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clinical Cancer Research 2005, 11:1918-1927.
97. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., Kim A.L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicology and Applied Pharmacology 2007, 224:274-283.
98. Kundu J.K., Surh Y.J. Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutation Research 2004, 555:65-80.
99. Wu J.M., Hsieh T.C. Resveratrol: a cardioprotective substance. Annals of the New York Academy of Sciences 2011, 1215:16-21.
100. Goldberg D.M., Yan J., Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clinical Biochemistry 2003, 36:79-87.
101. Mannal P.W., Alosi J.A., Schneider J.G., McDonald D.E., McFadden D.W. Pterostilbene inhibits pancreatic cancer in vitro. Journal of Gastrointestinal Surgery 2010, 14:873-879.
102. Hong Y.B., Kang H.J., Kim H.J., Rosen E.M., Dakshanamurthy S., Rondanin R., Baruchello R., Grisolia G., Daniele S., Bae I. Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells. Experimental and Molecular Medicine 2009, 41:151-160.
103. Bernhaus A., Ozsvar-Kozma M., Saiko P., Jaschke M., Lackner A., Grusch M., Horvath Z., Madlener S., Krupitza G., Handler N., Erker T., Jaeger W., Fritzer-Szekeres M., Szekeres T. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Investigational New Drugs 2009, 27:393-401.
104. Sun W., Wang W., Kim J., Keng P., Yang S., Zhang H., Liu C., Okunieff P., Zhang L. Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Advances in Experimental Medicine and Biology 2008, 614:179-186.
105. Zhou J.H., Cheng H.Y., Yu Z.Q., He D.W., Pan Z., Yang D.T. Resveratrol induces apoptosis in pancreatic cancer cells. Chinese Medical Journal 2011, 124:1695-1699.
106. Shamim U., Hanif S., Albanyan A., Beck F.W., Bao B., Wang Z., Banerjee S., Sarkar F.H., Mohammad R.M., Hadi S.M., Azmi A.S. Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. Journal of Cellular Physiology 2012, 227:1493-1500.
107. Bortolotti C., Kunit T., Moder A., Hufnagl C., Schmidt S., Hartl A., Langelueddecke C., Furst J., Geibel J.P., Ritter M., Jakab M. The phytostilbene resveratrol induces apoptosis in INS-1E rat insulinoma cells. Cellular Physiology and Biochemistry 2009, 23:245-254.
108. Mo W., Xu X., Xu L., Wang F., Ke A., Wang X., Guo C. Resveratrol inhibits proliferation and induces apoptosis through the hedgehog signaling pathway in pancreatic cancer cell. Pancreatology 2011, 11:601-609.
109. Ding X.Z., Adrian T.E. Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 2002, 25:e71-76.
110. Cui J., Sun R., Yu Y., Gou S., Zhao G., Wang C. Antiproliferative effect of resveratrol in pancreatic cancer cells. Phytotherapy Research 2010, 24:1637-1644.
111. Roy S.K., Chen Q., Fu J., Shankar S., Srivastava R.K. Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PloS One 2011, 6:e25166.
112. Hambrock A., de Oliveira Franz C.B., Hiller S., Grenz A., Ackermann S., Schulze D.U., Drews G., Osswald H. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. The Journal of Biological Chemistry 2007, 282:3347-3356.
113. Chen Q., Ganapathy S., Singh K.P., Shankar S., Srivastava R.K. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PloS One 2010, 5:e15288.
114. Oi N., Jeong C.H., Nadas J., Cho Y.Y., Pugliese A., Bode A.M., Dong Z. Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A(4)hydrolase. Cancer Research 2010, 70:9755-9764.
115. Golkar L., Ding X.Z., Ujiki M.B., Salabat M.R., Kelly D.L., Scholtens D., Fought A.J., Bentrem D.J., Talamonti M.S., Bell R.H., Adrian T.E. Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. Journal of Surgical Researh 2007, 138:163-169.
116. Kotha A., Sekharam M., Cilenti L., Siddiquee K., Khaled A., Zervos A.S., Carter B., Turkson J., Jove R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Molecular Cancer Therapeutics 2006, 5:621-629.
117. Shankar S., Nall D., Tang S.N., Meeker D., Passarini J., Sharma J., Srivastava R.K. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PloS One 2011, 6:e16530.
118. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
119. Gracia-Sancho J., Villarreal G., Zhang Y., Garcia-Cardena G. Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotective phenotype. Cardiovasc Research 2010, 85:514-519.
120. Paluszczak J., Krajka-Kuzniak V., Baer-Dubowska W. The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicology Letters 2010, 192:119-125.
121. Tili E., Michaille J.J., Adair B., Alder H., Limagne E., Taccioli C., Ferracin M., Delmas D., Latruffe N., Croce C.M. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 2010, 31:1561-1566.
122. Gupta S.C., Kannappan R., Reuter S., Kim J.H., Aggarwal B.B. Chemosensitization of tumors by resveratrol. Annals of the New York Academy of Sciences 2011, 1215:150-160.
123. Harikumar K.B., Kunnumakkara A.B., Sethi G., Diagaradjane P., Anand P., Pandey M.K., Gelovani J., Krishnan S., Guha S., Aggarwal B.B. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. International Journal of Cancer 2010, 127:257-268.
124. Fulda S., Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Research 2004, 64:337-346.